Mantle cell lymphoma
- Authors: Vorob’ev V.I.1, Tumian G.S.2,3, Falaleeva N.A.4, Ptushkin V.V.1, Osmanov E.A.3,5, Poddubnaya I.V.2, Baikov V.V.6, Kovrigina A.M.7,8, Nevol’skikh A.A.4, Ivanov S.A.4, Khailova Z.V.4, Gevorkian T.G.3
-
Affiliations:
- Botkin City Clinical Hospital
- Russian Medical Academy of Continuous Professional Education
- Blokhin National Medical Research Center of Oncology
- National Medical Research Radiological Center
- Sechenov First Moscow State Medical University (Sechenov University)
- Pavlov First Saint Petersburg State Medical University
- Academy of Postgraduate Education
- National Medical Research Center of Hematology
- Issue: Vol 22, No 3 (2020)
- Pages: 6-23
- Section: Guidelines
- URL: https://journals.rcsi.science/1815-1434/article/view/52478
- DOI: https://doi.org/10.26442/18151434.2020.3.200377
- ID: 52478
Cite item
Full Text
Abstract
Mantle cell lymphoma. Clinical recommendations
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
V. I. Vorob’ev
Botkin City Clinical Hospital
Author for correspondence.
Email: or@hpmp.ru
Cand. Sci. (Med.), Botkin City Clinical Hospital
Russian Federation, MoscowG. S. Tumian
Russian Medical Academy of Continuous Professional Education; Blokhin National Medical Research Center of Oncology
Email: or@hpmp.ru
D. Sci. (Med.), Prof., Russian Medical Academy of Continuous Professional Education, Blokhin National Medical Research Center of Oncology
Russian Federation, MoscowN. A. Falaleeva
National Medical Research Radiological Center
Email: or@hpmp.ru
D. Sci. (Med.), Tsyba Medical Radiological Research Center – branch of the National Medical Research Radiological Center
Russian Federation, ObninskV. V. Ptushkin
Botkin City Clinical Hospital
Email: or@hpmp.ru
D. Sci. (Med.), Prof., Botkin City Clinical Hospital
Russian Federation, MoscowE. A. Osmanov
Blokhin National Medical Research Center of Oncology; Sechenov First Moscow State Medical University (Sechenov University)
Email: or@hpmp.ru
D. Sci. (Med.), Prof., Botkin City Clinical Hospital, Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation, Obninsk; MoscowI. V. Poddubnaya
Russian Medical Academy of Continuous Professional Education
Email: or@hpmp.ru
ORCID iD: 0000-0002-0995-1801
D. Sci. (Med.), Prof., Acad. RAS, Russian Medical Academy of Continuous Professional Education
Russian Federation, MoscowV. V. Baikov
Pavlov First Saint Petersburg State Medical University
Email: or@hpmp.ru
D. Sci. (Med.), Prof., Pavlov First Saint Petersburg State Medical University
Russian Federation, Saint PetersburgA. M. Kovrigina
Academy of Postgraduate Education; National Medical Research Center of Hematology
Email: or@hpmp.ru
D. Sci. (Biol.), Prof., Academy of Postgraduate Education, National Medical Research Center of Hematology
Russian Federation, MoscowA. A. Nevol’skikh
National Medical Research Radiological Center
Email: or@hpmp.ru
D. Sci. (Med.), Tsyba Medical Radiological Research Center – branch of the National Medical Research Radiological Center
Russian Federation, ObninskS. A. Ivanov
National Medical Research Radiological Center
Email: or@hpmp.ru
D. Sci. (Med.), Prof. RAS, Tsyba Medical Radiological Research Center – branch of the National Medical Research Radiological Center
Russian Federation, ObninskZh. V. Khailova
National Medical Research Radiological Center
Email: or@hpmp.ru
Cand. Sci. (Med.), Tsyba Medical Radiological Research Center – branch of the National Medical Research Radiological Center
Russian Federation, ObninskT. G. Gevorkian
Blokhin National Medical Research Center of Oncology
Email: or@hpmp.ru
Deputy Director, Blokhin National Medical Research Center of Oncology
Russian Federation, MoscowReferences
- Carbone PP et al. Report of the Committee on Hodgkin’s Disease Staging Classification. Cancer Res 1971; 31 (11): 1860–1.
- Демина Е.А. и др. Общие принципы диагностики лимфом. Российские клинические рекомендации по диагностике и лечению злокачественных лимфопролиферативных заболеваний. Под ред. И.В. Поддубной, В.Г. Савченко. 2018; c. 9–27.
- [Demina E.A. et al. General principles of lymphoma diagnosis. Russian clinical guidelines for the diagnosis and treatment of malignant lymphoproliferative diseases. Ed. I.V. Poddubnaya, V.G. Savchenko. 2018; p. 9–27 (in Russian).]
- Воробьев В.И., Тумян Г.С. Лимфома из клеток мантии. Российские клинические рекомендации по диагностике и лечению злокачественных лимфопролиферативных заболеваний. Под ред. И.В. Поддубной, В.Г. Савченко. 2018; c. 68–80.
- [Vorobiev V.I., Tumyan G.S. Mantle cell lymphoma. Russian clinical guidelines for the diagnosis and treatment of malignant lymphoproliferative diseases. Ed. I.V. Poddubnaya, V.G. Savchenko. 2018; p. 68–80 (in Russian).]
- Zelenetz AD et al. B-cell lymphomas. NCCN Clinical Practice Guidelines in Oncology. Version 5. 2019.
- Dreyling M et al. Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017; 28 (Suppl. 4): iv62–iv71.
- Gill S et al. [18F]Fluorodeoxyglucose positron emission tomography scanning for staging, response assessment, and disease surveillance in patients with mantle cell lymphoma. Clin Lymphoma Myeloma 2008; 8 (3): 159–65.
- Howard OM et al. Rituximab and CHOP Induction Therapy for Newly Diagnosed Mantle-Cell Lymphoma: Molecular Complete Responses Are Not Predictive of Progression-Free Survival. J Clin Oncol 2002; 20 (5): 1288–94.
- LaCasce AS et al. Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL Database. Blood 2012; 119 (9): 2093–9.
- Lenz G et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantiy improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: Results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 2005; 23 (9): 1984–92.
- Bernstein SH et al. A phase II multicenter trial of hyperCVAD MTX/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213. Ann Oncol 2013; 24 (6): 1587–93.
- Damon LE et al. Immunochemotherapy and autologous stem- cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909. J Clin Oncol 2009; 27 (36): 6101–8.
- Sun T et al. Fluorescence in situ hybridization: method of choice for a definitive diagnosis of mantle cell lymphoma. Am J Hematol 2003; 74 (1): 78–84.
- Alavi A et al. Fluorodeoxyglucose-positron-emission tomography findings in mantle cell lymphoma. Clin Lymphoma Myeloma Leuk 2011; 11 (3): 261–6.
- Swerdlow SH et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon, France: International Agency for Research in Cancer (IARC). Ed. Swerdlow SH, Campo E, Harris NL et al. 2017.
- Dreyling M et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood 2005; 105 (7): 2677–84.
- Fenske TS, Carreras T, Zhang M. Outcome of patients with mantle-cell lymphoma undergoing autologous versus reduced-intensity allogenic transplantation. Ann Oncol 2011; 22 (Suppl. 4): Abstract 018.
- Visco C et al. Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation. J Clin Oncol 2013; 31 (11): 1442–9.
- Rummel MJ et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: An open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 2013; 381 (9873): 1203–10.
- Geisler CH. Front-line therapy of mantle cell lymphoma. Haematologica 2010; 95: 1241–3.
- Kluin-Nelemans HC et al. Treatment of older patients with mantle-cell lymphoma. N Engl J Med 2012; 367 (6): 520–31.
- Kahl BS et al. Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: A pilot study from the Wisconsin Oncology Network. Ann Oncol 2006; 17 (9): 1418–23.
- Hilal T et al. Rituximab maintenance therapy for mantle cell lymphoma: A systematic review and meta-analysis. Am J Hematol 2018; 93 (10): 1220–6.
- Rule S et al. Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies. Br J Haematol 2017; 179 (3): 430–8.
- Ruan J et al. Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma. Blood 2018; 132 (19): 2016–25.
- Romaguera JE et al. Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma. Br J Haematol 2010; 150 (2): 200–8.
- Martin P et al. Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol 2009; 27 (8): 1209–13.
- Hermine O et al. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. Lancet 2016; 388 (10044): 565–75.
- Merli F et al. Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi. Br J Haematol 2012; 156 (3): 346–53.
- Chihara D et al. Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center. Br J Haematol 2016; 172 (1): 80–8.
- Geisler CH et al. Nordic MCL2 trial update: Six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: Still very long survival but late relapses do occur. Br J Haematol 2012; 158 (3): 355–62.
- Eskelund CW et al. 15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau. Br J Haematol 2016; 175 (3): 410–18.
- Pott C et al. R-CHOP/R-DHAP Compared to R-CHOP Induction Followed by High Dose Therapy with Autologous Stem Cell Transplantation Induces Higher Rates of Molecular Remission In MCL: Results of the MCL Younger Intergroup Trial of the European MCL Network. Blood 2010; 116 (21).
- Le Gouill S et al. Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma. N Engl J Med 2017; 377 (13): 1250–60.
- Hoster E, Pott C. Minimal residual disease in mantle cell lymphoma: insights into biology and impact on treatment. Hematol Am Soc Hematol Educ Progr 2016; 2016 (1): 437–45.
- Cheminant M et al. Minimal residual disease monitoring by 8-color flow cytometry in mantle cell lymphoma: an EU-MCL and LYSA study. Haematologica 2016; 101 (3): 336–45.
- Gatt ME, Grisaro S. Central nervous system prophylaxis in mantle cell lymphoma. Blood 2009; 114 (26): 5402–3.
- Crocchiolo R et al. Tandem autologous-allogeneic stem cell transplantation as a feasible and effective procedure in high-risk lymphoma patients. Haematologica 2015; 100 (10): e423–e427.
- Dreyling M et al. Treatment for patients with relapsed/refractory mantle cell lymphoma: European-based recommendations. Leuk Lymphoma 2018; 59 (8): 1814–28.
- Weigert O et al. High Dose Cytarabine Salvage Regimen Combined with Bortezomib Is Feasible and Highly Effective in Relapsed Mantle Cell Lymphoma. Blood 2006; 108 (11): 2449.
- Gironella M et al. Rituximab Plus Gemcitabine and Oxaliplatin As Salvage Therapy in Patients with Relapsed/Refractory Mantle-Cell Lymphoma. Blood 2012; 120 (21).
- Corazzelli G et al. Gemcitabine, ifosfamide, oxaliplatin and rituximab (R-GIFOX), a new effective cytoreductive/mobilizing salvage regimen for relapsed and refractory aggressive non-Hodgkin’s lymphoma: Results of a pilot study. Ann Oncol 2006; 17 (Suppl.): 4.
- Corazzelli G et al. Long-term results of gemcitabine plus oxaliplatin with and without rituximab as salvage treatment for transplant-ineligible patients with refractory/relapsing B-cell lymphoma. Cancer Chemother Pharmacol 2009; 64 (5): 907–16.
- Friedberg JW et al. The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma. Blood 2011; 117 (10): 2807–12.
- Wang ML et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 2013; 369 (6): 507–16.
- Wang ML et al. Long-term follow-up of MCL patients treated with single-agent ibrutinib: Updated safety and efficacy results. Blood 2015; 126 (6): 739–45.
- Dreyling M et al. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: An international, randomised, open-label, phase 3 study. Lancet 2016; 387 (10020): 770–8.
- Wang ML et al. Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial. Lancet Oncol 2016; 17 (1): 48–56.
- Trněný M et al. Lenalidomide versus investigator’s choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial. Lancet. Oncol. 2016; 17 (3): 319–31.
- Chong EA et al. Combination of Lenalidomide and Rituximab Overcomes Rituximab Resistance in Patients with Indolent B-cell and Mantle Cell Lymphomas. Clin Cancer Res 2015; 21 (8): 1835–42.
- Le Gouill S et al. Reduced-intensity conditioning allogeneic stem cell transplantation for relapsed/refractory mantle cell lymphoma: A multicenter experience. Ann Oncol 2012; 23 (10): 2695–703.
- Soubeyran P, Gressin R. Treatment of the elderly patient with mantle cell lymphoma. Hematology 2016; 2016 (1): 425–31.
- Flinn IW et al. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood 2014; 123 (19): 2944–52.
- Gressin R et al. Frontline Therapy with the Ribvd Regimen Elicits High Clinical and Molecular Response Rates and Long PFS in Elderly Patients Mantle Cell Lymphoma (MCL); Final Results of a Prospective Phase II Trial By the Lysa Group. Blood. 2014; 124 (21): 148.
- Robak T et al. Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study. Lancet Oncol 2018; 19 (11): 1449–58.
- Spurgeon SE et al. Cladribine plus rituximab is an effective therapy for newly diagnosed mantle cell lymphoma. Leuk Lymphoma 2011; 52 (8): 1488–94.
- Kluin-Nelemans HC et al. Treatment of Older Patients With Mantle Cell Lymphoma (MCL): Long-Term Follow-Up of the Randomized European MCL Elderly Trial. J Clin Oncol 2020; 38 (3): 248–56.
- Robak T et al. Rituximab combined with cladribine or with cladribine and cyclophosphamide in heavily pretreated patients with indolent lymphoproliferative disorders and mantle cell lymphoma. Cancer 2006; 107 (7): 1542–50.
- Coleman M et al. Prednisone, etoposide, procarbazine, and cyclophosphamide (PEP-C) oral combination chemotherapy regimen for recurring/refractory lymphoma: low-dose metronomic, multidrug therapy. Cancer 2008; 112 (10): 2228–32.
- Владимирова Л.Ю. и др. Практические рекомендации по профилактике и лечению тошноты и рвоты у онкологических больных. Практические рекомендации Российского общества клинической онкологии. Лекарственное лечение злокачественных опухолей. Поддерживающая терапия в онкологии. 2018; с. 502–11.
- [Vladimirova L.Iu. et al. Prakticheskie rekomendatsii po profilaktike i lecheniiu toshnoty i rvoty u onkologicheskikh bol’nykh. Prakticheskie rekomendatsii Rossiiskogo obshchestva klinicheskoi onkologii. Lekarstvennoe lechenie zlokachestvennykh opukholei. Podderzhivaiushchaia terapiia v onkologii. 2018; p. 502–11 (in Russian).]
- Барях Е.А., Мякова Н.В., Поддубная И.В. Профилактика и лечение синдрома лизиса опухоли. Российские клинические рекомендации по диагностике и лечению злокачественных лимфопролиферативных заболеваний. Под ред. И.В. Поддубной, В.Г. Савченко. 2018; с. 251–3.
- [Bariakh E.A., Miakova N.V., Poddubnaya I.V. Profilaktika i lechenie sindroma lizisa opukholi. Rossiiskie klinicheskie rekomendatsii po diagnostike i lecheniiu zlokachestvennykh limfoproliferativnykh zabolevanii. Pod red. I.V. Poddubnoy, V.G. Savchenko. 2018; s. 251–3 (in Russian).]
- Aapro M и др. Клинические рекомендации по лечению анемии у больных злокачественными новообразованиями. М.: Ассоциация онкологов России, 2014.
- [Aapro M et al. Clinical guidelines for the treatment of anemia in patients with malignant neoplasms. Moscow: Association of Oncologists of Russia, 2014 (in Russian).]
- Орлова Р.В. и др. Практические рекомендации по лечению анемии при злокачественных новообразованиях. Практические рекомендации Российского общества клинической онкологии. Лекарственное лечение злокачественных опухолей. Поддерживающая терапия в онкологии. 2018; с. 494–501.
- [Orlova R.V. et al. Prakticheskie rekomendatsii po lecheniiu anemii pri zlokachestvennykh novoobrazovaniiakh. Prakticheskie rekomendatsii Rossiiskogo obshchestva klinicheskoi onkologii. Lekarstvennoe lechenie zlokachestvennykh opukholei. Podderzhivaiushchaia terapiia v onkologii. 2018; s. 494–501 (in Russian).]
- Абузарова Г.Р. и др. Обезболивание взрослых и детей при оказании медицинской помощи. Методические рекомендации. М.: ФГБОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России, 2016.
- [Abuzarova G.R. et al. Anesthesia for adults and children in the provision of medical care. Guidelines. Moscow: FGBOU IN RNIMU im. N.I. Pirogova Minzdrava Rossii, 2016 (in Russian).]
- Абузарова Г.Р. Лечение болевого синдрома у онкологических больных. Российские клинические рекомендации по диагностике и лечению злокачественных лимфопролиферативных заболеваний. Под ред. И.В. Поддубной, В.Г. Савченко. 2018; c. 278–88.
- [Abuzarova G.R. Lechenie bolevogo sindroma u onkologicheskikh bol’nykh. Rossiiskie klinicheskie rekomendatsii po diagnostike i lecheniiu zlokachestvennykh limfoproliferativnykh zabolevanii. Pod red. I.V. Poddubnoy, V.G. Savchenko. 2018; c. 278–88 (in Russian).]
- Cheson BD et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25 (5): 579–86.
- Paul KL. Rehabilitation and exercise considerations in hematologic malignancies. Am J Phys Med Rehabil 2011; 90 (5; Suppl. 1): S88–94.
- Hoster E et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 2008; 111 (2): 558–65.
- Schaffel R et al. Prognostic impact of proliferative index determined by quantitative image analysis and the international prognostic index in patients with mantle cell lymphoma. Ann Oncol 2010; 21 (1): 133–9.
- Yelvington BJ. Subcutaneous Rituximab in Follicular Lymphoma, Chronic Lymphocytic Leukemia, and Diffuse Large B-Cell Lymphoma. J Adv Pract Oncol 2018; 9 (5): 530–4.
- Davies A et al. Subcutaneous Rituximab for the Treatment of B-Cell Hematologic Malignancies: A Review of the Scientific Rationale and Clinical Development. Adv Ther 2017; 34 (10): 2210–31.
- García‐Muñoz R et al. Safety of switching from intravenous to subcutaneous rituximab during first‐line treatment of patients with non‐Hodgkin lymphoma: the Spanish population of the MabRella study. Br J Haematol 2020; 188 (5): 661–73.
- Macdonald D et al. A canadian perspective on the subcutaneous administration of rituximab in non-Hodgkin lymphoma. Curr Oncol 2017; 24 (1): 33–9.
- Delarue R et al. CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: A phase 2 study from the Groupe d’Etude des Lymphomes de l’Adulte. Blood 2013; 121 (1): 48–53.
- Geisler CH et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: A nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 2008; 112 (7): 2687–93.
- Dreyling M, Ferrero S, Hermine O. How to manage mantle cell lymphoma. Leukemia 2014; 28 (11): 2117–30.
- Oken MM et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5 (6): 649–55.